Adel S. Girgis

Adel S. Girgis is a distinguished researcher in medicinal chemistry affiliated with King Saud University, known for designing pharmaceutical compounds targeting critical health issues like inflammation and viral diseases. His work spans selective COX-2 inhibitors, antiviral agents for SARS-CoV-2, and computational-experimental integration in drug discovery.

Key research areas include:

• Development of COX-2 inhibitors for anti-inflammatory therapy
• Antiviral compound design against SARS-CoV-2
• QSAR studies for drug optimization
• VEGFR-2 inhibitors in cancer treatment
• Hybrid molecular architectures (e.g., fluoroquinolone–dichloroacetic acid hybrids)

His publications in journals like ChemMedChem and European Journal of Medicinal Chemistry highlight expertise in chemical synthesis, biological evaluation, and computational modeling. With over 2,689 citations and an H-index of 30, his work demonstrates significant academic influence.